Exclusive Summary

• The originator's core patents have expired or are expiring in numerous countries, providing a clear market entry window for generics.
• As a first-line therapy recommended by the WHO and major global guidelines, TAF targets a massive and growing patient pool of nearly 300 million people with Hepatitis B and tens of millions with HIV.
• It offers clear clinical value with significant renal and bone safety advantages over the older generation TDF, making it the preferred choice for treatment upgrades.
• The generic version offers the same therapeutic efficacy as the originator at a significantly lower cost, possessing strong price competitiveness and helping to expand patient access, especially for public health programs and in emerging markets.